Search for: All records

Photoelectrochemical (PEC) water splitting is a promising technology for green hydrogen production by harnessing solar energy. Traditionally, this sustainable approach is studied under light intensity of 100 mW/cm²mimicking the natural solar irradiation at the Earth’s surface. Sunlight can be easily concentrated using simple optical systems like Fresnel lens to enhance charge carrier generation and hydrogen production in PEC water splitting. Despite the great potentials, this strategy has not been extensively studied and faces challenges related to the stability of photoelectrodes. To prompt the investigations and applications, this work outlines the best practices and protocols for conducting PEC solar water splitting under concentrated sunlight illumination, incorporating our recent advancements and providing some experimental guidelines. The key factors such as light source calibration, photoelectrode preparation, PEC cell configuration, and long-term stability test are discussed to ensure reproducible and high performance. Additionally, the challenges of the expected photothermal effect and the heat energy utilization strategy are discussed. 

Abstract The paucity of targeted therapies for triple‐negative breast cancer (TNBC) causes patients with this aggressive disease to suffer a poor clinical prognosis. A promising target for therapeutic intervention is the Wnt signaling pathway, which is activated in TNBC cells when extracellular Wnt ligands bind overexpressed Frizzled7 (FZD7) transmembrane receptors. This stabilizes intracellular β‐catenin proteins that in turn promote transcription of oncogenes that drive tumor growth and metastasis. To suppress Wnt signaling in TNBC cells, this work develops therapeutic nanoparticles (NPs) functionalized with FZD7 antibodies and β‐catenin small interfering RNAs (siRNAs). The antibodies enable TNBC cell specific binding and inhibit Wnt signaling by locking FZD7 receptors in a ligand unresponsive state, while the siRNAs suppress β‐catenin through RNA interference. Compared to NPs coated with antibodies or siRNAs individually, NPs coated with both agents more potently reduce the expression of several Wnt related genes in TNBC cells, leading to greater inhibition of cell proliferation, migration, and spheroid formation. In two murine models of metastatic TNBC, the dual antibody/siRNA nanocarriers outperformed controls in terms of inhibiting tumor growth, metastasis, and recurrence. These findings demonstrate suppressing Wnt signaling at both the receptor and mRNA levels via antibody/siRNA nanocarriers is a promising approach to combat TNBC.